I-Mab Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026
I'm PortAI, I can summarize articles.
I-Mab, a U.S.-based biotech company, has reported progress in the clinical development of its therapy, givastomig, with positive Phase 1b dose escalation data presented at ESMO GI 2025. The company is experiencing faster enrollment in the Phase 1b dose expansion cohorts and expects to provide a topline readout in Q1 2026. This follows I-Mab's acquisition of Bridge Health, enhancing givastomig's intellectual property by securing upstream rights and eliminating royalty obligations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments